Virtus Biotech ETF BBP
103.75 USD -0.78 (-0.75%)
At closeNov 10, 2026, 4:00 PM EST
103.75 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
102.61 Day range 104.15
73.97 52-week range 110.05
- YTD
- +29.82%
- 1 year
- +38.31%
News
zacks.com ETFs That You May Consider Amid a Strengthening Biotech Outlook Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
globenewswire.com BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels - In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12…
zacks.com Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
seekingalpha.com BBP: The Biotech ETF That Filters For FDA-Approved Drugs Virtus Biotech ETF (BBP) is rated a buy for its focused exposure to FDA-approved biotech firms and strong recent outperformance. BBP's equal-weight, quarterly rebalancing strategy efficiently…
globenewswire.com BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 - Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for…
benzinga.com ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data showing durable bladder cancer outcomes.
globenewswire.com BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418's rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically…
benzinga.com ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check ImmunityBio stock dips despite Anktiva trial validation, FDA ad warning, and bullish analyst targets amid strong year-to-date gains.
benzinga.com ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use The NCCN adds ImmunityBio Anktiva plus BCG to bladder cancer guidelines, expanding treatment use and boosting outlook.
benzinga.com Why Is ImmunityBio Stock Soaring On Friday? ImmunityBio stock rises in premarket after NK cell therapy trials show safety and scalable production of billions of cells.
globenewswire.com BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 - Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified…
benzinga.com ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug ImmunityBio resubmits the ANKTIVA application to the FDA after a prior setback.
benzinga.com Why Is ImmunityBio Stock Gaining Tuesday? ImmunityBio shares climb in Tuesday's premarket after Saudi regulators encourage a key cancer treatment submission amid BCG shortages.
globenewswire.com BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study - All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company's prior studies
globenewswire.com BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today…
benzinga.com Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth.
globenewswire.com BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically significant change, in contrast to the…
globenewswire.com BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) - Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio believes there is an opportunity to pursue Accelerated Approval in the…
globenewswire.com BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program - Receipt of RMAT Designation is based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial, which showed functional improvements in all dosed patients indicating that BBP-812…
benzinga.com FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.
zacks.com 4 Best-Performing Sector ETFs of June We have highlighted four top-performing ETFs from different sectors that have led the way in June.
zacks.com Biotech ETFs Stage Solid Comeback at the Start of 2024 The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting…
zacks.com 5 Least-Hurt Biotech ETFs of the Last Week Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
seekingalpha.com Can Health Care Stocks Outperform Again In 2023? How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
zacks.com 2 Sector ETFs Hovering Around a 52-Week High We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.
zacks.com 5 Best Areas of Q3 of 2022 & Their Top ETFs These ETF areas won in the third quarter of 2022.
zacks.com Biotech & Crypto -- Best ETF Areas of Last Week Biotech and cryptocurrency -- two ETF areas outperformed last week.
etftrends.com Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the…
benzinga.com 2 New Biotech ETFs Offer Unique Industry Focus